삼성제약

001360KOSPI의약품 제조업

54.8 / 100

Reference Date: 2026-06-10

Financial Score23.0 / 40

News Sentiment18.8 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Plunged 26.8% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Samsung Pharmaceutical operates in pharmaceutical manufacturing and sales, biopharma, and health food sectors, distributing a wide range of products including specialty and over-the-counter drugs. The company is advancing clinical trials for pancreatic cancer treatment GV1001 and Alzheimer's disease, with revenue reaching 460.7 billion KRW in 2025.

Number of Employees

87people

Average Salary

66.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

10.95Industry Average 11.935.0Point

In line with industry avg

PBR

1.05Industry Average 0.892.5Point

Higher than industry avg (caution)

ROE

10.18Industry Average 4.017.0Point

2.5x industry avg (excellent)

Debt Ratio

3.37Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼5.4% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼2.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -10.9% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 75

Positive
모아라이프플러스, 삼성제약과 '르피랩 메이신 스포츠' 공급 계약…약.....
삼성제약과의 공급 계약 체결로 모아라이프플러스의 시장 진출 확대 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 1,347Won52-week high 2,21052-week low 1,343

1-month return0.0Point

1m -26.75% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral기업지배구조보고서공시2026-06-01
Neutral분기보고서 (2026.03)2026-05-15